Mary Kay Inc. Awards 10 Grants to Young Innovators at 2025 Regeneron International Science and Engineering Fair
28.5.2025 22:29:00 CEST | Business Wire | Press Release
Mary Kay Inc., a global advocate for furthering young women’s education and encouraging youth to follow their STEM dreams, returned for a second year as a Special Awards Organization at the Regeneron International Science and Engineering Fair (Regeneron ISEF) in Columbus, Ohio. Ten grants totaling nearly $10,000 were awarded to standout high school-aged students excelling in innovative projects spanning topics from finding cures for cancers affecting women to sustainable packaging innovation and protecting our planet’s most valuable resources.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250528325390/en/
Kristin Dasaro, Director, Package Engineering and Sustainability at Mary Kay, greets Brazilian cancer researcher, Carolina de Araujo Pereira da Silva, who received back-to-back awards from Mary Kay for innovative findings in the malignancy of tumors. (Photo Credit: Mary Kay Inc.)
Each year, the event convenes nearly 2,000 participants representing more than 60 countries, with a total award pool offering over $9 million in awards and scholarships and invitations to corporate and academic events with elite global leaders in STEM.
Celebrating its 75th year, ISEF, a program of Society for Science, is the world’s largest pre-college global STEM competition. Through a global network of local, regional, and national science fairs, millions of students are encouraged to explore their passion for scientific inquiry. Each spring, a group of these students is selected as finalists and offered the opportunity to compete for approximately $9 million in awards and scholarships at the annual Regeneron ISEF.
“The ingenuity, passion, and innovation demonstrated by these young STEM leaders are awe-inspiring,” said Carrissa Dowdy, Manager of Product Formulation at Mary Kay. “Their work has the potential to transform industries, drive sustainable advancements, and accelerate major breakthroughs in fields like cancer research, material science, and environmental engineering. Mary Kay is proud to stand behind them as they shape the future of STEM.”
MEET THE STUDENT STEM LEADERS | ||
1. | Pragathi Kasani-Akula (GA, USA) | |
Multi-Color Magneto-Fluorescent Nanoarchitectures for the Targeted Identification of Exosomes of Triple Negative Breast Cancer | ||
2. | Grace Liu (NY, USA) | |
Evaluating Gender Disparities Due to Decision-Making Under Uncertainty in Entrepreneurship: A Panel Data Analysis | ||
3. | Alina Albeik (VA, USA) | |
Implications of Resveratrol on Memory Retention in Dugesia tigrina | ||
4. | Kaili Tseng and Leila Gheysar (CA, USA) | |
Bombyx mori Antimicrobial Peptides: A Novel and Sustainable Catalyst for Cancer Cell Growth Inhibition and Death | ||
5. | Elisabeth Fischermann and Tom Kressbach (Bavaria, Germany) | |
On the Hunt for Free Radicals With a Blue Light Reaction | ||
6. | Ela Doruk Korkmaz (Istanbul, Turkey) | |
Investigation of Potential Anti-Cancer Impacts of Coffee Bean-Derived Exosomes Through Anti-Proliferative and Apoptosis Inducing Effects on Melanoma Skin Cancer Cells via Mitogen-Activated Protein Kinase Signaling Pathway | ||
7. | Carolina de Araujo Pereira da Silva* (Rio de Janeiro, Brazil) | |
Salinomycin as a Molecular Trojan Horse for Targeting Mn-Induced Malignancy in Aggressive Tumors | ||
8. | Sofia Nunes (Maranhao, Brazil) | |
Formulation of Low-Cost Artificial Skin for Cellular Regeneration and Severe Burns Treatment | ||
9. | Margareth Ac-ac (Negros Oriental, Philippines) | |
SKIMP: Artificial Intelligence- Convolutional Neural Network (CNN) Portable Skin Cancer Detection Device With Skin Cancer Notifier Python-Based Program | ||
10. | Kamila Rotger-Costas and Miranda Sanz-Alvarez (Guaynabo and Caguas, Puerto Rico) | |
EcoReishiFlex: An Innovative Sustainable Biodegradable Plastic Alternative Made From Ganoderma lucidum (Reishi Fungi) Polysaccharides | ||
*Carolina de Araujo Pereira da Silva is a two-time Mary Kay Young Women in STEM grant recipient for her outstanding contributions to the cancer research field. Her 2024 prize money was utilized toward furthering her presented project - Rock the Metals! Investigating Manganese as a Trigger of Malignancy and Metal Transporters as Targets in Cancer Treatment which elevated her 2025 award-winning submission.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty brand in Texas in 1963 with one goal: to enrich women’s lives. That dream has blossomed into a global company with millions of independent sales force members in more than 40 markets. For over 60 years, the Mary Kay opportunity has empowered women to define their own futures through education, mentorship, advocacy, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in preserving our planet for future generations, protecting women impacted by cancer and domestic abuse, and encouraging youth to follow their dreams. Learn more at marykayglobal.com. Find us on Facebook, Instagram, and LinkedIn, or follow us on X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250528325390/en/
Contacts
Mary Kay Inc. Corporate Communications
newsroom.marykay.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fnewsroom.maryk
ay.com%2F&esheet=54261648&newsitemid=20250528325390&lan=en-US&anchor=newsroom.ma
rykay.com&index=6&md5=196684b837f2443552204094cb420cc8
972.687.5332 or media@mkcorp.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom